{
    "organizations": [],
    "uuid": "860e8d42446627ed6089a54427ce111b519c556b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cytori-provides-update-on-us-manuf/brief-cytori-provides-update-on-u-s-manufacturing-and-eu-approval-plans-for-ati-0918-liposomal-doxorubicin-idUSASC09Y76",
    "ord_in_thread": 0,
    "title": "BRIEF-Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Cytori Therapeutics Inc:\n* CYTORI PROVIDES UPDATE ON U.S. MANUFACTURING AND EU APPROVAL PLANS FOR ATI-0918, LIPOSOMAL DOXORUBICIN\n* CYTORI THERAPEUTICS - INTENDS TO FIRST SEEK EUROPEAN APPROVAL FOR ITS DRUG, APPLIED FOR, GOT EMA APPROVAL TO FILE FOR CENTRALIZED EU APPROVAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-30T20:40:00.000+03:00",
    "crawled": "2018-05-01T19:51:47.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "cytori",
        "therapeutic",
        "inc",
        "cytori",
        "provides",
        "update",
        "manufacturing",
        "eu",
        "approval",
        "plan",
        "liposomal",
        "doxorubicin",
        "cytori",
        "therapeutic",
        "intends",
        "first",
        "seek",
        "european",
        "approval",
        "drug",
        "applied",
        "got",
        "ema",
        "approval",
        "file",
        "centralized",
        "eu",
        "approval",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}